If we recall that approximately 25% of total weight loss in persons with obesity is accounted for by FFM, the authors found that fat free mass accounted for 33%, 39%, and 25% of total weight loss for retatrutide ( Phase 2 data only, not yet FDA approved), semaglutide and tirzepatide respectively whereas fat mass loss accounted for 67%, 61%, and 75% respectively
Assessment for dry mouth examining saliva flow and tissue moisture
You can reach Damian on Signal at damiangarde.67
Phase 3 clinical trials are under way (see ClinicalTrials.gov for current registered studies), and whilst early Phase 2 results are encouraging, retatrutide is not legally available as a prescribed medicine in the UK outside of approved clinical trial settings
Lerner A, Freire de Carvalho J, Kotrova A, Shoenfeld Y (2022) Gluten-free diet can ameliorate the symptoms of non-celiac autoimmune diseases